11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Coumadin

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Warfarin

Warfarin

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005;127:2049-56.

  2. Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost. 2010;104:471-84.

  3. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005;112:1687-91.

  4. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost. 2009;101:938-42.

  5. Gomberg-Maitland M, Wenger NK, Feyzi J, Lengyel M, Volgman AS, Petersen P et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J. 2006;27:1947-53.

  6. Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol. 2014;113(3):485-90.

  7. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation. 2001;103:2365-70.

  8. Jönsson AC, Ek J, Kremer C. Outcome of men and women after atrial fibrillation and stroke. Acta Neurol Scand. 2015;132(2):125-31.

  9. Wettermark B, Persson A, von Euler M. Secondary prevention in a large stroke population: a study of patients' purchase of recommended drugs. Stroke. 2008;39(10):2880-5.

  10. Loikas D, Forslund T, Wettermark B, Schenck-Gustafsson K, Hjemdahl P, von Euler M. Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Non-Vitamin K Oral Anticoagulants. Am J Cardiol. 2017;120(8):1302-1308.

  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-04-17.]

  1. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005;127:2049-56.
  2. Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost. 2010;104:471-84.
  3. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005;112:1687-91.
  4. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost. 2009;101:938-42.
  5. Gomberg-Maitland M, Wenger NK, Feyzi J, Lengyel M, Volgman AS, Petersen P et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J. 2006;27:1947-53.
  6. Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol. 2014;113(3):485-90.
  7. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation. 2001;103:2365-70.
  8. Jönsson AC, Ek J, Kremer C. Outcome of men and women after atrial fibrillation and stroke. Acta Neurol Scand. 2015;132(2):125-31.
  9. Wettermark B, Persson A, von Euler M. Secondary prevention in a large stroke population: a study of patients' purchase of recommended drugs. Stroke. 2008;39(10):2880-5.
  10. Loikas D, Forslund T, Wettermark B, Schenck-Gustafsson K, Hjemdahl P, von Euler M. Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Non-Vitamin K Oral Anticoagulants. Am J Cardiol. 2017;120(8):1302-1308.
  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-04-17.]